COMMITMENT LETTER
Principles for Responsible Clinical Trial Data Sharing

We, leaders of the pharmaceutical industry, believe that:

- Our commitment to data sharing will enhance research and scientific knowledge, advance patient care and improve public health;
- The dramatic increase in the amount of information that research-based companies are making available to researchers will enhance collaborations in the interest of improved research;
- The interests of patients remain at the heart of everything we do in relation to responsible clinical trial data sharing;
- The industry must be allowed to flourish in order to fulfill its promise in serving patients, past, present and future.

On behalf of (insert company name), I hereby confirm our adherence to the PhRMA and EFPIA Principles for Responsible Clinical Data Sharing ("the Principles").
We are therefore committed to establishing policies, procedures or guidelines to implement the Principles.

We also support EFPIA's decision to incorporate the Principles within the appropriate EFPIA Code(s) by mid-2015, which will allow monitoring and oversight of the companies' compliance with the Principles.

Company: Pfizer Inc

Signed on behalf of the company by

Name: John Young
Position in the company: Group President

Representing and engaging the company in regard of its EFPIA membership obligations

Date: 3/18/14
Signature: 

John Young
Group President
Global Established Pharma Business